ArticleExperimental and therapeutic medicine2021
Assessment of acute pancreatitis severity via determination of serum levels of hsa-miR-126-5p and IL-6.
Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- miR-1-3p, as a novel diagnostic and prognostic biomarker, aggravates pancreatic acinar cell injury in acute pancreatitis by targeting GNPTAB.Hereditas · 2026Article
- Analysis of diagnostic efficacy of serum miR-126-5p levels for stratifying severity in pediatric acute appendicitis.BMC pediatrics · 2026Article
- Serum aberrant expression of miR-331-3p and its diagnostic value in severe pancreatitis.BMC gastroenterology · 2026Article
- Diagnostic and Prognostic Value of miR-574-3p in Acute Pancreatitis: Insights from Bioinformatics and in vitro Studies.Journal of inflammation research · 2026Article
- Role of Bifidobacterium animalis subsp. lactis BB-12 in mice with acute pancreatitis.AMB Express · 2025Article
- Role of Interleukin 6 in Acute Pancreatitis: A Possible Marker for Disease Prognosis.International journal of molecular sciences · 2024Review
- Cytokine Dynamics in Acute Pancreatitis: The Quest for Biomarkers from Acute Disease to Disease Resolution.Journal of clinical medicine · 2024Article
- Article
- Interleukins: pathophysiological role in acute pancreatitis.Archives of medical science : AMS · 2024Article
- Fighting Fire with Fire: Exosomes and Acute Pancreatitis-Associated Acute Lung Injury.Bioengineering (Basel, Switzerland) · 2022Review
- Alterations of the expression levels of glucose, inflammation, and iron metabolism related miRNAs and their target genes in the hypothalamus of STZ-induced rat diabetes model.Diabetology & metabolic syndrome · 2022Article
- Combined detection of procalcitonin, heparin-binding protein, and interleukin-6 is a promising assay to diagnose and predict acute pancreatitis.Journal of clinical laboratory analysis · 2021Article
- Diabetic Bone Marrow Cell Injection Accelerated Acute Pancreatitis Progression.Journal of immunology research · 2021Article
- Metoprolol combined with nicorandil on unstable angina pectoris can reduce incidence of cardiovascular events and inflammatory reactions.American journal of translational research · 2021Article
- Candidate circulating microRNA biomarkers in dogs with chronic pancreatitis.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early assessment of acute pancreatitis (AP) severity is key to its treatment. The present study aimed to explore the role of microRNAs (miRNAs/miRs) combined with inflammatory factors in determining AP severity. For this, serum pro-inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, IL-8 and IL-10)] and miRNAs [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.